We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · August 08, 2020

Effect of Reduced-Dose Capecitabine + Cetuximab as Maintenance for RAS Wild-Type Metastatic Colorectal Cancer

JAMA Network Open


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Network Open
Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial
JAMA Netw Open 2020 Jul 01;3(7)e2011036, L Wang, Y Liu, X Yin, W Fang, J Xiong, B Zhao, M Zhang, Y Zou, H Qiu, X Yuan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading